Hengrui Medicine H shares commence trading on HKEX

Jiangsu Hengrui Medicine announced the commencement of trading for its overseas listed foreign shares (H shares) on the main board of the Hong Kong Stock Exchange (HKEX) today, May 23, 2025, under the stock code "1276". The global offering comprised 224,519,800 H shares before any exercise of over-allotment options, with 48,271,800 shares offered in Hong Kong and 176,248,000 shares internationally. The H shares were priced at HKD 44.05 per share. Hengrui estimates net proceeds of approximately CNY 9.747 billion from the global offering, assuming the over-allotment option is not exercised. After the issuance, A-share holdings represent 96.60% of the company. The company's largest shareholders, Jiangsu Hengrui Medicine Group Co., Ltd. and Tibet Da Yuan Enterprise Management Co., Ltd., hold 23.29% and 14.43% respectively.